Skip to main content

Month: September 2022

Millrock Confirms Third Mineralization Layer Beneath the Core Eureka Zone By Assaying Historical Core Samples From the Nikolai (Ni-Cu-Co-PGE) Project, Alaska

Figure 1 View looking east along the Eureka Zone within a large mafic-ultramafic magmatic complex. Note: Outline of the Ultramafic complex and Eureka zone are approximate.Figure 2 Cross section view of Eureka Zone looking west, showing trace of holes FL-003 and FL-006 drilled by INCO in 1997.VANCOUVER, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) — Millrock Resources Inc. (TSX-V: MRO) (“Millrock”) is pleased to report additional assay results from the sampling of historical core from the Eureka Zone at its 100% owned Nikolai Project, which hosts nickel (Ni) – copper (Cu) – cobalt (Co) – platinum group elements (PGE) prospects. The Nikolai Project is located within Alaska’s Delta Mining District, approximately 130 kilometers by road south of Delta Junction and approximately 280 kilometers southeast of Fairbanks. The Eureka...

Continue reading

Surgalign Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Broadens Fortilink interbody product line to now include both titanium and 3D-printed polymer options DEERFIELD, Ill., Sept. 26, 2022 (GLOBE NEWSWIRE) — Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the expansion of its Fortilink product portfolio with the introduction and commercial launch of a new family of interbody fusion devices featuring TiPlus technology. The new implants include Fortilink-A with TiPlus technology for anterior lumbar interbody fusion (ALIF) procedures; Fortilink-TC and -TS with TiPlus technology for posterior lumbar interbody fusion (PLIF/TLIF) procedures; and Fortilink-C with TiPlus technology for anterior cervical discectomy and fusion (ACDF) procedures. The new family of...

Continue reading

Mullen Automotive’s ‘Strikingly Different’ Tour Kicks Off in California this October and in Nevada, November 2022

The Mullen FIVE “Strikingly Different” Tour commences on Oct. 27, 2022, at the Rose Bowl in Pasadena, California, and at the Las Vegas Motor Speedway in Las Vegas, Nevada, on Nov. 10, 2022.Mullen to Begin “Strikingly Different” Tour on Oct. 27, 2022 Tour kicks off at the Rose Bowl in Pasadena, California.BREA, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today the kickoff dates of its “Strikingly Different” Tour for the Mullen FIVE EV Crossover.  Mullen is proud to start the “Strikingly Different” Tour with the first stop in California on Oct 27 and 28 at the Rose Bowl in Pasadena, California. From there, the U.S. tour will continue to Las Vegas, Nevada, on Nov....

Continue reading

180 Life Sciences Issues Letter to Stockholders

PALO ALTO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) — 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody. Dear Fellow Stockholder, In mid-June, I wrote to update you on the status of our Company and our respective investments. In that letter, I provided an update regarding the Company’s clinical development plans, which remained on track then, and continue to remain on track today. As a reminder, 180 Life Sciences was founded on the belief that novel anti-inflammatory biologics that are already approved, such as anti-tumor necrosis factor (TNF), or adalimumab, could have the potential to address large unmet needs for a variety of additional indications. Currently,...

Continue reading

Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)

Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Paratek’s Management Team BOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use today announces that the company will host an update for investors on the global opportunity for NUZYRA® (omadacycline) in non-tuberculous mycobacteria (NTM) on Monday, Oct. 3 from 10:30 a.m. to noon Eastern time. During the webinar, Paratek Chief Executive Officer Evan Loh, M.D., and Chief Development and Regulatory Officer Randy Brenner will provide a corporate overview, update investors on the market opportunity for NTM...

Continue reading

LM Funding Commences Generation of Bitcoin Mining Revenue

TAMPA, FL, Sept. 26, 2022 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ:LMFA) (“LM Funding” or “LMFA”) today announced the energization of 848 S19J Pro Antminer Mining Machines (S19J Pro) at the Core Scientific Inc. facility in Calvert City, Kentucky. “We are excited to energize our first machines in my home state of Kentucky,” said Bruce M. Rodgers, Chairman and CEO of LM Funding and a Bowling Green, Kentucky native.  “We plan to sell our mined Bitcoin to pay operating expenses and reinvest the balance in the purchase and operation of additional Bitcoin mining machines.”  Rodgers finished by stating, “Generating Bitcoin revenue marks the successful execution to date of our cryptocurrency mining business strategy and next phase of growth for our Company.  We continue to believe all 5,400 machines will...

Continue reading

Biofrontera Inc.’s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards

WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics and medical device industries, has awarded the previously nominated Ameluz® marketing campaign, created by Biofrontera Inc. along with Elevate Healthcare, “Relaunch/Revitalization of the Year” and “Professional Website/Online Initiative of the Year” awards. These awards were announced at the 14th Annual Trailblazer Awards held September 22, 2022 in New York, where they also recognized the previously announced Trailblazer Brand Champion in Dermatology, Leslie Hopkins, Associate Director of Marketing at Biofrontera Inc. The winners will be featured...

Continue reading

HUMBL and Great Foods2Go Announce Strategic Technology Partnership

San Diego-based companies will collaborate on technology solutions for cloud kitchen and delivery services San Diego, California, Sept. 26, 2022 (GLOBE NEWSWIRE) — HUMBL, Inc. (OTC Markets: HMBL) announced today the formation of a strategic technology partnership with Great Foods2Go (GF2GO). Under the terms of the agreement, the two companies will integrate HUMBL’s mobile application, search engine and marketplace technologies in support of GF2GO and its sub-brand, 1Delivery. The partnership will utilize the full HUMBL platform including: HUMBL Wallet, HUMBL Pay, HUMBL Search Engine and HUMBL Marketplace technologies. The partnership will focus initially on the San Diego, California cloud kitchen location and be designed to expand across multiple locations. The location currently prepares and delivers over 2,000 food orders per...

Continue reading

Form 8.3 – [EMIS Group plc – 23 09 2022] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree EMIS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Form 8.3 – [GB Group plc – 23 09 2022] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree GB GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.